- Previous Close
169,700.00 - Open
165,800.00 - Bid 171,600.00 x --
- Ask 171,700.00 x --
- Day's Range
165,700.00 - 174,000.00 - 52 Week Range
152,666.67 - 200,952.38 - Volume
594,307 - Avg. Volume
506,886 - Market Cap (intraday)
37.772T - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield 714.29 (0.42%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
236,723.36
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
www.celltrion.comRecent News: 068270.KS
View MorePerformance Overview: 068270.KS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 068270.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 068270.KS
View MoreValuation Measures
Market Cap
36.94T
Enterprise Value
37.99T
Trailing P/E
82.98
Forward P/E
36.50
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.86
Price/Book (mrq)
2.12
Enterprise Value/Revenue
10.68
Enterprise Value/EBITDA
35.51
Financial Highlights
Profitability and Income Statement
Profit Margin
11.88%
Return on Assets (ttm)
1.50%
Return on Equity (ttm)
2.41%
Revenue (ttm)
3.56T
Net Income Avi to Common (ttm)
422.69B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.14T
Total Debt/Equity (mrq)
12.47%
Levered Free Cash Flow (ttm)
513.07B